VWF and Von Willebrand disease: Caplacizumab interferes with vWF, which is crucial for hemostasis, potentially leading to mucocutaneous bleeding similar to that in patients with von Willebrand disease [3]. Bleeding is generally mucocutaneous and manageable; dose interruption may be required for invasive procedures.